Sunovion Pharms Inc Drug Patent Portfolio

Sunovion Pharms Inc owns 1 orange book drug protected by 17 US patents Given below is the list of Sunovion Pharms Inc's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9259423 Method of treatment for mental disorders 23 Nov, 2031
Active
US9259423 Method of treatment for mental disorders 23 May, 2031
Active
US9827242 Method of treatment for mental disorders 23 May, 2031
Active
US8729085 Pharmaceutical composition 26 Nov, 2026
Active
US8883794 Pharmaceutical composition 26 Nov, 2026
Active
US9907794 Pharmaceutical composition 26 Nov, 2026
Active
US8729085 Pharmaceutical composition 26 May, 2026
Active
US8883794 Pharmaceutical composition 26 May, 2026
Active
US9555027 Pharmaceutical composition 26 May, 2026
Active
US9907794 Pharmaceutical composition 26 May, 2026
Active
USRE45573 Process for producing imide compound 23 Dec, 2025
Active
USRE45573 Process for producing imide compound 23 Jun, 2025
Active
US9174975 Remedy for integration dysfunction syndrome 20 Aug, 2024 Expired
US9174975 Remedy for integration dysfunction syndrome 20 Feb, 2024 Expired
US9815827 Agent for treatment of schizophrenia 20 Feb, 2024 Expired
US5532372 Imide derivatives, and their production and use 02 Jan, 2019 Expired
US5532372 Imide derivatives, and their production and use 02 Jul, 2018 Expired


Given below is the list of recent legal activities going on the following drug patents of Sunovion Pharms Inc.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 8th Year, Large Entity 04 May, 2022 US8883794 (Litigated)
Termination or Final Written Decision 07 Dec, 2021 US9815827
Payment of Maintenance Fee, 8th Year, Large Entity 10 Nov, 2021 US8729085 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 01 Sep, 2021 US9907794
Payment of Maintenance Fee, 4th Year, Large Entity 19 May, 2021 US9827242
Payment of Maintenance Fee, 4th Year, Large Entity 05 May, 2021 US9815827
Request for Trial Granted 09 Dec, 2020 US9815827
Payment of Maintenance Fee, 4th Year, Large Entity 20 Jul, 2020 US9555027
Petition Requesting Trial 05 Jun, 2020 US9815827
Post Issue Communication - Certificate of Correction 27 Jun, 2018 US9907794
Payment of Maintenance Fee, 4th Year, Large Entity 01 May, 2018 US8883794 (Litigated)
Patent Issue Date Used in PTA Calculation 06 Mar, 2018 US9907794
Recordation of Patent Grant Mailed 06 Mar, 2018 US9907794
Email Notification 15 Feb, 2018 US9907794
Issue Notification Mailed 14 Feb, 2018 US9907794


Sunovion Pharms Inc's Drug Patent Litigations

Sunovion Pharms Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 18, 2017, against patent number US9555027. The petitioner Par Pharmaceutical, Inc., challenged the validity of this patent, with Sumitomo Dainippon Pharma Co., Ltd. as the respondent. Click below to track the latest information on how companies are challenging Sunovion Pharms Inc's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US9815827 June, 2020 Final Written Decision
(07 Dec, 2021)
Sumitomo Dainippon Pharma Co., Ltd. et al. Slayback Pharma LLC et al.
US9555027 April, 2017 Terminated-Settled
(14 Aug, 2017)
Sumitomo Dainippon Pharma Co., Ltd. Par Pharmaceutical, Inc.


Sunovion Pharms Inc's Family Patents

Sunovion Pharms Inc drugs have patent protection in a total of 23 countries. It's US patent count contributes only to 25.4% of its total global patent coverage. 2 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Sunovion Pharms Inc Drug List

Given below is the complete list of Sunovion Pharms Inc's drugs and the patents protecting them.


1. Latuda

Latuda is protected by 17 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US9259423
(Pediatric)
Method of treatment for mental disorders 23 Nov, 2031
(7 years from now)
Active
US9259423 Method of treatment for mental disorders 23 May, 2031
(6 years from now)
Active
US9827242 Method of treatment for mental disorders 23 May, 2031
(6 years from now)
Active
US8729085
(Pediatric)
Pharmaceutical composition 26 Nov, 2026
(2 years from now)
Active
US8883794
(Pediatric)
Pharmaceutical composition 26 Nov, 2026
(2 years from now)
Active
US9907794
(Pediatric)
Pharmaceutical composition 26 Nov, 2026
(2 years from now)
Active
US8729085 Pharmaceutical composition 26 May, 2026
(1 year, 7 months from now)
Active
US8883794 Pharmaceutical composition 26 May, 2026
(1 year, 7 months from now)
Active
US9555027 Pharmaceutical composition 26 May, 2026
(1 year, 7 months from now)
Active
US9907794 Pharmaceutical composition 26 May, 2026
(1 year, 7 months from now)
Active
USRE45573
(Pediatric)
Process for producing imide compound 23 Dec, 2025
(1 year, 2 months from now)
Active
USRE45573 Process for producing imide compound 23 Jun, 2025
(8 months from now)
Active
US9174975
(Pediatric)
Remedy for integration dysfunction syndrome 20 Aug, 2024
(a month ago)
Expired
US9174975 Remedy for integration dysfunction syndrome 20 Feb, 2024
(7 months ago)
Expired
US9815827 Agent for treatment of schizophrenia 20 Feb, 2024
(7 months ago)
Expired
US5532372
(Pediatric)
Imide derivatives, and their production and use 02 Jan, 2019
(5 years ago)
Expired
US5532372 Imide derivatives, and their production and use 02 Jul, 2018
(6 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Latuda's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List